{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Li X"],"funding":["Beijing Chao-Yang Hospital"],"pagination":["1312-1319"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11147666"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(16)"],"pubmed_abstract":["<h4>Introduction</h4>Lung adenocarcinoma (LUAD) is a common pathological type of lung cancer. The presence of lymph node metastasis plays a crucial role in determining the overall treatment approach and long-term prognosis for early LUAD, therefore accurate prediction of lymph node metastasis is essential to guide treatment decisions and ultimately improve patient outcomes.<h4>Methods</h4>We performed transcriptome sequencing on T1 LUAD patients with positive or negative lymph node metastases and combined this data with The Cancer Genome Atlas Program cohort to identify potential risk molecules at the tissue level. Subsequently, by detecting the expression of these risk molecules by real-time quantitative PCR in serum samples, we developed a model to predict the risk of lymph node metastas"],"journal":["Thoracic cancer"],"pubmed_title":["A liquid biopsy assay for the noninvasive detection of lymph node metastases in T1 lung adenocarcinoma."],"pmcid":["PMC11147666"],"funding_grant_id":["22kcjjzd-6"],"pubmed_authors":["Li X","Li H","Gu Y","Shao MM","Hu B"],"additional_accession":[]},"is_claimable":false,"name":"A liquid biopsy assay for the noninvasive detection of lymph node metastases in T1 lung adenocarcinoma.","description":"<h4>Introduction</h4>Lung adenocarcinoma (LUAD) is a common pathological type of lung cancer. The presence of lymph node metastasis plays a crucial role in determining the overall treatment approach and long-term prognosis for early LUAD, therefore accurate prediction of lymph node metastasis is essential to guide treatment decisions and ultimately improve patient outcomes.<h4>Methods</h4>We performed transcriptome sequencing on T1 LUAD patients with positive or negative lymph node metastases and combined this data with The Cancer Genome Atlas Program cohort to identify potential risk molecules at the tissue level. Subsequently, by detecting the expression of these risk molecules by real-time quantitative PCR in serum samples, we developed a model to predict the risk of lymph node metastas","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jun","modification":"2026-07-02T03:19:15.302Z","creation":"2026-07-02T03:12:13.141Z"},"accession":"S-EPMC11147666","cross_references":{"pubmed":["38682829"],"doi":["10.1111/1759-7714.15315"]}}